doi: 10.1111/imj.12530.
Dilemmas in the compassionate supply of investigational cancer drugs
Affiliations
- PMID: 25201421
- DOI: 10.1111/imj.12530
Item in Clipboard
Dilemmas in the compassionate supply of investigational cancer drugs
Intern Med J.
2014 Sep.
Abstract
In Australia, patients who want to access medicines that are not yet approved have only two options: to enroll in a clinical trial if they are eligible, or obtain their medicine through 'compassionate supply', which is provided at the discretion of the manufacturer. In this article, we explore ethical issues associated with the provision of oncology medicines that are still in development, either prior to regulatory approval or government reimbursement.
Keywords: ethics; evidence-based medicine; health services accessibility; oncology.
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.
Comment in
-
Access to 'investigational' cancer drugs: perspective of a trainee.Intern Med J. 2015 Feb;45(2):235. doi: 10.1111/imj.12666. Intern Med J. 2015. PMID: 25650544 No abstract available.
Similar articles
-
Access to 'investigational' cancer drugs: perspective of a trainee.Intern Med J. 2015 Feb;45(2):235. doi: 10.1111/imj.12666. Intern Med J. 2015. PMID: 25650544 No abstract available.
-
Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines.J Med Ethics. 2010 Dec;36(12):791-4. doi: 10.1136/jme.2010.036442. Epub 2010 Sep 18. J Med Ethics. 2010. PMID: 20852303
-
[Second Opinion, Compassionate Use, and Clinical Trial].Cuad Bioet. 2017 Jan-Apr;28(92):127-128. Cuad Bioet. 2017. PMID: 28342439 Spanish. No abstract available.
-
Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.Expert Opin Investig Drugs. 2018 Feb;27(2):155-162. doi: 10.1080/13543784.2018.1430137. Epub 2018 Jan 22. Expert Opin Investig Drugs. 2018. PMID: 29353505 Free PMC article. Review.
-
Before It's Too Late: Multistakeholder Perspectives on Compassionate Access to Investigational Drugs for Pediatric Patients With Cancer.Am Soc Clin Oncol Educ Book. 2020 May;40:1-10. doi: 10.1200/EDBK_278995. Am Soc Clin Oncol Educ Book. 2020. PMID: 32412804 Review.
Cited by
-
An analysis of common ethical justifications for compassionate use programs for experimental drugs.BMC Med Ethics. 2016 Oct 18;17(1):60. doi: 10.1186/s12910-016-0145-x. BMC Med Ethics. 2016. PMID: 27756370 Free PMC article.
-
Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs.JAMA Netw Open. 2022 Nov 1;5(11):e2239766. doi: 10.1001/jamanetworkopen.2022.39766. JAMA Netw Open. 2022. PMID: 36318206 Free PMC article.
-
Ethics review in compassionate use.BMC Med. 2017 Jul 24;15(1):136. doi: 10.1186/s12916-017-0910-9. BMC Med. 2017. PMID: 28735571 Free PMC article.
-
Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.PLoS One. 2021 Dec 17;16(12):e0261478. doi: 10.1371/journal.pone.0261478. eCollection 2021. PLoS One. 2021. PMID: 34919568 Free PMC article.
-
Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.BMC Med. 2016 Feb 2;14:17. doi: 10.1186/s12916-016-0568-8. BMC Med. 2016. PMID: 26843367 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
